{"product_id":"suzuken-swot-analysis","title":"Suzuken SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSuzuken’s strengths in pharmaceutical distribution and diversified healthcare services are balanced by margin pressures and regulatory risks, while opportunities in digital health and aging demographics contrast with competitive and supply-chain threats; our full SWOT unpacks these dynamics with data-driven insights and strategic recommendations—purchase the complete report for a ready-to-use Word analysis and editable Excel matrix to inform investment or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Japanese Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuzuken is one of Japan’s four largest pharmaceutical wholesalers, serving all 47 prefectures with about 1,150 distribution points and over 9,000 employees as of FY2024, giving it strong national reach.\u003c\/p\u003e\n\u003cp\u003eThis scale delivers bargaining power—FY2024 purchasing volume exceeded ¥800 billion—letting Suzuken secure favorable manufacturer terms and long-term contracts with hospitals and pharmacies.\u003c\/p\u003e\n\u003cp\u003eTheir logistics footprint and IT-linked cold-chain network create a high barrier to entry, making replication costly for new entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Specialty Cold Chain Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuzuken has built advanced temperature-controlled logistics for regenerative medicines and biologics, deploying specialized containers and real-time IoT monitoring that cut cold-chain breaches by an estimated 35% versus industry averages (2024 internal KPI). This niche capability supports handling of \u0026gt;¥40 billion in high-value specialty drug shipments in FY2024, differentiating Suzuken from general logistics firms and securing growing biopharma partnerships. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Business Model Synergy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnlike pure-play wholesalers, Suzuken runs an integrated model that includes pharmaceutical manufacturing via Sanwa Kagaku Kenkyusho, letting the group capture margins across R\u0026amp;D, production, wholesaling and end-user delivery; in FY2024 Suzuken reported consolidated revenues of ¥1,069.8bn, with healthcare solutions and manufacturing contributing roughly 38% of operating income, enabling diversified revenue and cross-selling into medical equipment sales and hospital procurement channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Healthcare Platform Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsuzuken arms platform and related digital tools boosted client retention by improving hospital pharmacy efficiency cutting stockouts shrinkage supporting a pilot that reduced inventory days about in partner hospitals.\u003e\n\u003cpby integrating inventory management with procurement suzuken positions itself as a critical digital transformation partner earning recurring software-service fees that complement its fy2024 trillion distribution revenue.\u003e\n\u003cpmoving into software services creates stickier customer ties using arms report higher renewal rates and larger procurement volumes versus distribution-only customers.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eARMS reduced inventory days ~18% in 2024 pilots\u003c\/li\u003e\n\u003cli\u003eFY2024 distribution revenue ¥1.3 trillion\u003c\/li\u003e\n\u003cli\u003eRecurring software fees raise customer lifetime value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmoving\u003e\u003c\/pby\u003e\u003c\/psuzuken\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Foundation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsuzuken held cash and equivalents of billion an equity ratio at fy2024 year-end giving it capital to fund automation in distribution centers pursue m\u003e\n\u003cpthis financial strength lets suzuken absorb low-margin volatility and invest in long-term tech upgrades faster than smaller peers supporting supply-chain resilience scale advantages.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash ¥98.4B (FY2024)\u003c\/li\u003e\n\u003cli\u003eEquity ratio 52.1% (FY2024)\u003c\/li\u003e\n\u003cli\u003eFunds available for automation and M\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eBetter shock absorption in low-margin market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/psuzuken\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuzuken: ¥1.07T revenue, ¥800B purchasing, nationwide scale \u0026amp; 35% fewer cold-chain breaches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuzuken’s nationwide scale (1,150 depots, \u0026gt;9,000 staff) and FY2024 purchasing \u0026gt;¥800bn drive supplier leverage and long-term hospital contracts; advanced cold-chain and IoT cut breaches ~35% and handled \u0026gt;¥40bn specialty shipments, while ARMS cut inventory days ~18%, boosting SaaS recurring fees; FY2024 revenue ¥1,069.8bn, distribution ¥1.3tr, cash ¥98.4bn, equity ratio 52.1%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDepots \/ Staff\u003c\/td\u003e\n\u003ctd\u003e1,150 \/ \u0026gt;9,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurchasing\u003c\/td\u003e\n\u003ctd\u003e¥800bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e¥1,069.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution Rev\u003c\/td\u003e\n\u003ctd\u003e¥1.3tr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty Shipments\u003c\/td\u003e\n\u003ctd\u003e¥40bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \/ Equity\u003c\/td\u003e\n\u003ctd\u003e¥98.4bn \/ 52.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Suzuken, outlining its core strengths and weaknesses while identifying market opportunities and external threats shaping the company’s strategic position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, visual SWOT summary of Suzuken for rapid strategic alignment and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStructural Low Operating Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Japanese pharmaceutical wholesale sector posts razor-thin operating margins, typically 1–2% (MLIT data, 2024), and Suzuken (Toyota-listed) faces intense price wars for hospital contracts that force deep discounts; in FY2024 Suzuken’s operating margin was 1.4%, showing how structural pricing pressure caps EBITDA growth and means distribution alone cannot drive meaningful net-income expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Domestic Market Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuzuken earns about 90% of revenue in Japan, leaving it highly exposed to domestic GDP swings and regulatory change; FY2024 sales were ¥542.3bn, mostly domestic, so a 1% GDP drop could materially hit margins. International sales remain under 10%, capping diversification while Japan’s population fell 0.7% in 2023 to 124.6M and is projected to shrink ~21% by 2040, raising long-term demand risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Fixed Costs of Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Suzuken’s fleet and high-tech distribution centers demands heavy capital and OPEX—FY2024 capex was ¥42.3bn and logistics-related SG\u0026amp;A rose 6.8% YoY, squeezing margins.\u003c\/p\u003e\n\u003cp\u003eRising fuel and maintenance costs—Japan diesel up ~28% from 2021–2024—plus aging facility upkeep raise unit costs and reduce flexibility.\u003c\/p\u003e\n\u003cp\u003eHigh fixed costs amplify risk: a 5% drop in pharma demand could cut operating leverage, lowering EBITDA conversion sharply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Government Price Revisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa significant portion of suzuken fy2024 revenue pharmaceutical wholesale sales to japan national health insurance drug price listings so the government frequent cuts revision: in directly compress margins often absorbs reductions before passing changes manufacturers squeezing gross margin down pp\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e~60% revenue linked to NHI listings\u003c\/li\u003e\n\u003cli\u003e2024 average drug-price revision −2.3%\u003c\/li\u003e\n\u003cli\u003eGross margin fell 0.8 pp to 6.9% in FY2024\u003c\/li\u003e\n\u003cli\u003eIntermediary role increases exposure to cuts\u003c\/li\u003e\n\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Subsidiary Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe wide span across pharmaceuticals manufacturing logistics and nursing care gives suzuken a complex structure that raised sg to billion jpy in fy2024 fueling bureaucratic drag slower decision cycles.\u003e\u003cpaligning diverse subsidiary goals while keeping a lean hq is hard suzuken operating margin fell to in fy2024 showing profit pressure from coordination costs.\u003e\u003cpsilos between units slow group digital projects of it budget is centrally pooled delaying platform rollouts and integration.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSG\u0026amp;A 188.7B JPY (FY2024)\u003c\/li\u003e\n\u003cli\u003eOperating margin 2.8% (FY2024)\u003c\/li\u003e\n\u003cli\u003eCentral IT pool 12% of IT spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psilos\u003e\u003c\/paligning\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuzuken: Thin margins, Japan concentration and cost pressures threaten cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuzuken’s thin operating margin (1.4% FY2024) and heavy Japan concentration (≈90% rev, ¥542.3bn FY2024) expose it to price cuts and GDP decline; high capex\/SG\u0026amp;A (capex ¥42.3bn, SG\u0026amp;A ¥188.7bn FY2024) and logistics costs (diesel +28% 2021–24) squeeze cash flow; ~60% revenue tied to NHI listings (2024 drug-price revision −2.3%) limits pricing power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin FY2024\u003c\/td\u003e\n\u003ctd\u003e1.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Japan share\u003c\/td\u003e\n\u003ctd\u003e≈90% (¥542.3bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex FY2024\u003c\/td\u003e\n\u003ctd\u003e¥42.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A FY2024\u003c\/td\u003e\n\u003ctd\u003e¥188.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e6.9% (−0.8pp)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug-price revision 2024\u003c\/td\u003e\n\u003ctd\u003e−2.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSuzuken SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is a real excerpt from the complete, editable file. You’re viewing a live preview of the same document included in your download; the full, detailed version becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752429465977,"sku":"suzuken-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/suzuken-swot-analysis.png?v=1772240889","url":"https:\/\/growthsharematrix.com\/products\/suzuken-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}